

Appendix 1 - nominated candidates

3 March 2022

Adam Steensberg

Chairman of the Board of Directors since July 2021 (member since 2020)

Education: MD, Doctor of Medical Science, Copenhagen, MBA IMD Switzerland.

About: Adam Steenberg has 15 years of experience in the biotech- and pharmaceutical industry. He has a broad experience from R&D strategy, medical, science from all stages of development, including regulatory submissions. Other ongoing assignments: Chief Medical Officer, EVP, Head of R&D at Zealand Pharma



Charlotte Videbæk

Member of the Board of Directors since 2020

Education: MD, Doctor of Medical Science, Specialist in Neurology, Copenhagen.

About: Charlotte Videbæk has more than ten years of clinical experience, followed by more than 20 years of experience within international pharma- and biotech and project management. Other ongoing assignments: Consultant and founder of C-ApS



Peter Birk

Member of the Board of Directors since 2020

Education: Ph.D. in Protein Engineering, INSA Toulouse, France and Master of Molecular Biology, University of Southern Denmark, Denmark.

About: Peter Birk has a proven biotech track record where he has held several Board positions and both strategic and operational managerial positions. Other ongoing assignments: Partner at Accelerace Management A/S and Chairman of the Board of Directors of Monta Biosciences ApS.



Martin Olin

Member of the Board of Directors since 2020

Education: M.Sc, Business & Auditing, Copenhagen Business School.

About: Martin Olin has more than 20 years of life science experience, CEO and CFO leadership experience in international organisations.

Other ongoing assignments: Chief Executive Officer at BerGenBio ASA



Flemming Steen Jensen

Member of the Board of Directors since 2020

Education: M.Sc. in Pharmacy, University of Copenhagen, Denmark.

About: Flemming Jensen has more than 30 years of experience in the pharmaceutical Industry, where he held positions within development, manufacturing, supply chain, QA, engineering and senior management.

Other ongoing assignments: Senior Vice President at Ascendis Pharma A/S, member of the Board of Directors of Genau & More A/S and Allero Therapeutics B.V.

**Rachel Curtis Gravesen**

Observer to the Board of Directors since January 2022

Education: University of Cambridge, St John's College, UK, MA in Archaeology &

Anthropology, St John's College About: Rachel has over 25 years' experience in leadership, business and communication, with multiple roles in investor relations and communications. Rachel has previously held roles at Genmab and Novo Nordisk as well as working as a journalist at CNBC Nordic and the BBC. Other ongoing assignments: Owner of Curtis Consult

